Posted on Jul 2, 2020

SciTech Development

SciTech Development, LLC, a clinical stage specialty pharmaceutical company focused on novel, advanced drug delivery mechanisms for use with cancer therapeutics, is pleased to announced that it has received IRB Approval to enter the clinic at Rush University Medical Center (RUMC) for ST-001 nanoFenretinide treatment of T-cell non-Hodgkin's lymphoma (NHL). SciTech’s Investigational New Drug Application (IND) for ST-001 nanoFenretinide treatment of T-cell non-Hodgkin's lymphoma (NHL) was accepted last December. Additionally, the FDA has granted Orphan Drug Designation status for ST-001 in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Solid preclinical and clinical data makes the case for the use of fenretinide in the treatment of additional blood disorders and solid tumors such as small cell lung, breast, pancreatic, neuroblastoma and other cancers. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-263-4887 | eth@scitechdevelopment.com
Contact Us
Message sent. We'll get back to you soon.